Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

doi:10.1182/blood.2025032806

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Blood - 27 Aug 2026

Riecke Armin, Robrecht Sandra, Yosifov Deyan Y, Schneider Christof, Giza Adam, Müller Lothar, Vehling-Kaiser Ursula, Eckart Michael, Freier Werner, Schöttker Björn, Gaska Tobias, Reiser Marcel, Fink Anna-Maria, Fischer Kirsten, Eichhorst Barbara, Hallek Michael, Langerbeins Petra, Stilgenbauer Stephan, Tausch Eugen

Abstract excerpt

ABSTRACT: Watch-and-wait is standard of care in asymptomatic early-stage chronic lymphocytic leukemia (CLL). The CLL12 trial investigated ibrutinib vs placebo for patients with early-stage CLL with intermediate to very high risk of progression, improving event-free survival (EFS) but not overall survival (OS). Building on these findings, our analysis examined whether a benefit could be identified within distinct...